Eli Lilly’s Financial Results Beat Wall Street Estimates
Eli Lilly (LLY) reported Q3 earnings of $7.48 per share, exceeding estimates of $6.26. Revenue reached $24.40 billion, surpassing forecasts of $22.61 billion. The company raised its 2026 revenue outlook to $91-$92 billion. Mounjaro and Zepbound sales beat expectations, while Foundayo missed targets. LLY stock has risen 58% in the past year.
How this was made
The 30-second read
Why it matters
The combination of Q3 beats and a raised full-year revenue outlook is a direct repricing catalyst for LLY, while product-level details (Mounjaro and Zepbound exceeding expectations) provide the mechanism behind the guidance change.
Market read
Traders can update positioning immediately based on the raised 2026 revenue outlook and the disclosed product-level beats, despite a noted miss for Foundayo.
What to watch
The article notes profits are slightly lower due to acquisitions, so margin and integration costs may temper the earnings quality of the guidance raise.
Background
Eli Lilly is a leading obesity and diabetes drug developer, with Zepbound and Mounjaro as key growth drivers and ongoing pipeline expansion via acquisitions.
Ticker impact
Eli Lilly reported Q3 EPS of $7.48 and revenue of $24.40B, both beating consensus, and raised full-year revenue guidance to $91B-$92B.
Likely upward pressure as the market reprices growth expectations from the raised full-year revenue outlook and strong weight-loss/diabetes sales.
The article discloses a fresh earnings beat plus an explicit guidance increase, with supporting product-level outperformance (Mounjaro and Zepbound) that directly underpins the forecast change.
Market effects
Reinforces bullish read-through for GLP-1 and obesity/diabetes pharma demand expectations, potentially supporting sentiment across the sector.
US large-cap pharma sentiment likely improves as guidance raises signal sustained demand.
Global obesity/diabetes treatment demand narrative strengthens, with international sales growth cited for both Mounjaro and overall revenue.
Counterpoint
Foundayo missed quarterly targets, and full-year EPS guidance is only slightly below the prior range midpoint, which could limit upside despite revenue strength.
Key entities
- companyEli Lilly
Reported Q3 EPS and revenue beats, raised 2026 revenue guidance, and cited accelerating Zepbound and Mounjaro demand.
- productZepbound
Global Q3 sales of $5.35B, up 49% year over year, above analyst expectations.
- productMounjaro
Worldwide Q3 revenue rose 65% to $10.72B, above expectations; international sales grew 93%.
- productFoundayo
New weight-loss pill; Q3 sales of $184M missed the $229M forecast, though management said ramp-up continues.
- acquisition_targetMerida Biosciences
Lilly bought Merida Biosciences to develop treatments for autoimmune diseases and allergies.
